

Admission arterial partial pressure of carbon dioxide (paCO₂) and outcomes after out-of-hospital cardiac arrest: a single-centre retrospective cohort study

Mei Li*, Qinghui Hu, Lifeng Du

Emergency department, PKUCare CNOOC Hospital Tianjin, China

ABSTRACT

Background: Admission arterial partial pressure of carbon dioxide (PaCO₂) is readily available after out-of-hospital cardiac arrest (OHCA), but its independent prognostic value is uncertain and prior evidence is conflicting. We evaluated the association of admission PaCO₂ with one-month mortality and neurological outcome, and quantified its incremental prognostic value.

Material and Methods: In a single-center retrospective cohort of 617 adults resuscitated from OHCA (2014-2023), patients were stratified by admission PaCO₂ (≤ 50 , >50 -70 and >70 mmHg). The primary outcome was one-month all-cause mortality; the secondary outcome was neurological status at one month by Cerebral Performance Category (CPC), analyzed as a dichotomous, ordinal and survivor-restricted endpoint. Associations were estimated with multi-variable logistic and ordinal regression adjusted for age, sex, witnessed arrest, bystander cardiopulmonary resuscitation (CPR), call-to-arrival time, initial shockable rhythm, prehospital return of spontaneous circulation (ROSC) and arrest etiology. PaCO₂ was modelled continuously (per 10 mmHg) and categorically; sensitivity analyses used alternative cut-points, and discrimination was quantified by the area under the receiver-operating-characteristic curve (AUC). A simplified Directed Acyclic Graph was used heuristically for variable selection; however, we explicitly acknowledge that post-resuscitation physiology represents a complex feedback system. Therefore, formal causal effect estimation was not attempted, and all analyses are strictly associational and prognostic.

Results: One-month mortality was 73.6% (454/617) and rose across PaCO₂ groups (49.7%, 81.1%, and 90.7%; $p < 0.001$). Each 10-mmHg increase in PaCO₂ was associated with higher mortality after adjustment for measured confounders (adjusted odds ratio [aOR] 1.45, 95% CI 1.24-1.70; $p < 0.001$), with a concordant gradient for the ordinal CPC outcome (common aOR 1.53, 95% CI 1.31-1.79) and among survivors (aOR 1.91, 95% CI 1.25-2.91). The graded association was robust across categorization schemes but was attenuated after additional adjustment for concurrent acid-base and gas-exchange markers (lactate, base excess, PaO₂; aOR 0.80, 95% CI 0.64-1.01; $p = 0.063$), consistent with strong collinearity between PaCO₂ and acid-base status. Adding PaCO₂ to a clinical model produced a minimal incremental improvement in discrimination of uncertain clinical utility (AUC 0.794 to 0.816; Δ AUC 0.022, 95% CI 0.002-0.043; optimism-corrected AUC 0.802). Calibration was assessed via bootstrap validation (calibration slope: 0.98, 95% CI 0.89-1.07; calibration-in-the-large: -0.04, 95% CI -0.21 to 0.13), indicating adequate agreement between predicted and observed risks.

Conclusions: In this decade-long cohort, higher admission PaCO₂ was associated with increased one-month mortality and worse neurological outcome after OHCA, but added minimal discrimination beyond established clinical factors. Because admission PaCO₂ is a treatment-dependent exposure - determined by CPR duration and quality, airway and ventilation management, ventilator settings and the ROSC-to-sampling interval, none of which were available - independent prognostic value cannot be established from these data, and the association is most plausibly a signal of arrest severity and of the resuscitation delivered. Attenuation after adjustment for metabolic acidosis is consistent with shared pathophysiology, although mediator overadjustment cannot be excluded. Admission PaCO₂ is immediate, inexpensive and universally available, but prospective studies capturing resuscitation timings, CPR quality and standardized ventilation are required before any prognostic role can be claimed.

Keywords: arterial partial pressure of carbon dioxide; outcomes; out-of-hospital cardiac arrest; retrospective cohort study

Received: 26 august 2025 / Accepted: 16 july 2026

Published under CC BY 4.0 license

* Correspondence to: Mei Li, Emergency department, PKUCare CNOOC Hospital Tianjin, China, Email: 2512819962@qq.com

■ INTRODUCTION

Out-of-hospital cardiac arrest (OHCA) remains a major public-health challenge, with survival to hospital discharge below 10% in most large series and lower still in some national reports [1]. Although cardiopulmonary resuscitation (CPR) and post-resuscitation care have advanced, the narrow therapeutic window and the complexity of the post-cardiac-arrest syndrome characterized by systemic ischemia-reperfusion injury and myocardial dysfunction continue to limit improvements in neurological prognosis [2, 3]. Established prognostic indicators such as age, initial rhythm, and time to return of spontaneous circulation (ROSC) provide preliminary guidance, yet their independent predictive utility remains inconsistent across heterogeneous patient populations [4, 5]. A critical but under-elucidated factor in the post-resuscitation phase is the role of arterial carbon dioxide tension (PaCO_2). The post-arrest state often involves a profound ventilation/perfusion mismatch, which compromises cerebral blood flow autoregulation and may exacerbate secondary ischemic brain injury [6]. Current literature presents conflicting evidence: while some studies correlate hypercapnia with prolonged CPR duration [7], others suggest that hypocapnia is more strongly associated with poor neurological recovery [8-10]. Furthermore, it remains unclear whether admission PaCO_2 serves merely as a surrogate marker for the "ischemic-ventilatory debt" accumulated during arrest or as an independent driver of injury [11]. Crucially, PaCO_2 measured on admission is inherently a post-resuscitation, treatment-dependent variable, influenced by early ventilation strategies and the time from ROSC to blood gas sampling. Unlike fixed baseline characteristics, its interpretation as a prognostic marker is therefore confounded by resuscitative interventions.

We hypothesized that admission PaCO_2 would be associated with one-month mortality and neurological outcome after adjustment for established prognostic factors, and that this association would be modified by arrest etiology. However, given the observational design and the post-resuscitation timing of PaCO_2 measurement, we explicitly framed our analysis as prognostic association rather than causal effect estimation. Using a decade-long dataset (2014-2023) from a high-volume emergency department, we evaluated the prognostic value of admission PaCO_2 while accounting for key confounders, and quantified its incremental discriminative value beyond an established clinical model. A

secondary aim was to examine whether the association differed between cardiac and non-cardiac arrests, given the pathophysiological heterogeneity of OHCA.

■ METHODS

Study design and population

We conducted a retrospective cohort study of adults with OHCA who presented to the emergency department of Peking University Hospital of Marine Oil, Tianjin, China, over a ten-year period from 2014 to 2023. Eligible patients were adults (≥ 18 years) with physician-confirmed OHCA who received resuscitative interventions and for whom an admission arterial blood-gas (ABG) sample and one-month outcome data were available. Patients were excluded if they were younger than 18 years, had a pre-existing terminal illness with limited life expectancy, were pregnant or lactating, or lacked an admission ABG sample or one-month outcome data. After application of these criteria, 617 patients formed the analytic cohort (Figure 1). The study was approved by the Institutional Review Board of Peking University Hospital of Marine Oil, which waived the requirement for informed consent given the retrospective design; all data were de-identified. The study was conducted in accordance with the Declaration of Helsinki and is reported in line with the STROBE guidance for observational studies.

Data collection and variable definitions

Data were extracted from electronic medical records and comprised demographic characteristics (age, sex); prehospital variables (witnessed status, bystander CPR, call-to-arrival time, initial shockable rhythm, prehospital ROSC); arrest etiology; and admission physiological and ABG parameters (PaCO_2 , PaO_2 , pH, lactate, base excess).

Admission ABG samples were obtained immediately on hospital arrival; the interval from ROSC and from advanced airway placement to sampling was not consistently recorded, so admission PaCO_2 may partly reflect early ventilatory management (see Limitations).

Outcomes

The primary outcome was one-month all-cause mortality. Neurological status at one month was assessed with the Cerebral Performance Category (CPC), in which CPC 5 denotes death. Because death is coded




Fig. 1. Patient selection and stratification

Patient selection and stratification. Flow of adults with OHCA (2014–2023) through eligibility screening to the analytic cohort (N = 617), stratified by admission PaCO₂ group

within the CPC scale, neurological outcome was analyzed in three complementary ways: (i) dichotomized as favorable (CPC 1–2) versus unfavorable (CPC 3–5); (ii) as an ordinal variable (CPC 1–5); and (iii) restricted to one-month survivors, as unfavorable neurological status (CPC 3–4) versus favorable (CPC 1–2).

PaCO₂ was analyzed primarily as a continuous variable, with effects expressed per 10-mmHg increase to avoid the loss of information inherent in categorization. For descriptive and clinical interpretability, patients were also grouped as ≤50, >50–70, and >70 mmHg, corresponding approximately to normocapnia/mild, moderate, and severe hypercapnia. Because any threshold is to some extent arbitrary, we performed prespecified sensitivity analyses using standard clinical categories (≤45, 46–60, >60 mmHg) and empirical tertiles, in addition to the continuous model.

Statistical analysis

Continuous variables are reported as median (interquartile range, IQR) and compared with the Kruskal-Wallis test; categorical variables are reported as n (%) and compared with the χ^2 test. Multivariable logistic regression modelled one-month mortality, with PaCO₂ entered continuously (per 10 mmHg) and categorically. The primary (clinical) model adjusted for age, sex, witnessed arrest, bystander CPR, call-to-arrival

time, shockable initial rhythm, prehospital ROSC, and etiology. A secondary sensitivity model additionally included concurrent metabolic markers (lactate, base excess, PaO₂). Because these acid-base variables are strongly collinear with PaCO₂ and lie downstream on the causal pathway, this model was explicitly framed as a conservative sensitivity analysis to explore shared pathophysiology, rather than as a primary estimate of an "independent" effect.

Ordinal (proportional-odds) regression was used for the CPC outcome. Firth's penalized logistic regression was used for the survivor-only endpoint due to the low number of events. The proportional odds assumption was tested using the Brant test. Prognostic discrimination was quantified with the AUC, with 95% confidence intervals (CI). Effect modification by etiology was tested with a PaCO₂ × etiology interaction term. Collinearity was assessed with variance-inflation factors. A two-sided $p < 0.05$ was considered significant. For internal validation, we used bootstrap resampling (2000 iterations) to obtain an optimism-corrected AUC and to compute the 95% CI for the change in AUC (Δ AUC) when PaCO₂ was added to the clinical model. Calibration of the clinical-plus-PaCO₂ model was assessed by the calibration slope and calibration-in-the-large with bootstrapped confidence intervals.

Missing data

The analytic dataset was complete for all variables included in the models; no imputation was required. Patients without an admission ABG sample or without one-month outcome data were not eligible for the cohort, as reflected in the study flow diagram (Figure 1). To assess potential selection bias, we compared the baseline characteristics of included patients versus those excluded due to missing ABG or outcome data (Supplementary Table S6).

RESULTS

Cohort and baseline characteristics

The cohort comprised 617 patients (median age 67 years [IQR 57-76]; 367 [59.5%] male). Arrest was wit-

nessed in 253 patients (41.0%), bystander CPR was performed in 97 (15.7%), the initial rhythm was shockable in 143 (23.2%), and prehospital ROSC was documented in 78 (12.6%). Etiology was cardiac in 395 patients (64.0%) and non-cardiac in 222 (36.0%). Median admission PaCO₂ was 58.0 mmHg (IQR 47.2-68.4; range 18.0-101.6). Higher PaCO₂ was accompanied by more severe acidosis (lower pH, more negative base excess, higher lactate), fewer favorable prehospital features (less witnessed arrest, less bystander CPR, fewer shockable rhythms, less prehospital ROSC), and a higher proportion of non-cardiac etiology (Table 1).

Primary outcome: one-month mortality

One-month mortality was 73.6% overall and increased monotonically across PaCO₂ groups: 49.7% (95/191),

Table 1: Baseline characteristics by admission PaCO₂ group

Variable	Overall (N = 617)	≤50 mmHg (n = 191)	>50-70 mmHg (n = 286)	>70 mmHg (n = 140)	p
Age, years	67 (57-76)	66 (56-75)	66 (55-75)	72 (60-81)	0.002
Male sex	367 (59.5)	130 (68.1)	167 (58.4)	70 (50.0)	0.004
Witnessed arrest	253 (41.0)	97 (50.8)	120 (42.0)	36 (25.7)	<0.001
Bystander CPR	97 (15.7)	45 (23.6)	40 (14.0)	12 (8.6)	<0.001
Shockable initial rhythm	143 (23.2)	82 (42.9)	45 (15.7)	16 (11.4)	<0.001
Prehospital ROSC	78 (12.6)	45 (23.6)	28 (9.8)	5 (3.6)	<0.001
Call-to-arrival time, min	22.3 (17.8-28.7)	21.6 (17.5-27.2)	21.9 (17.5-28.5)	24.1 (18.8-30.2)	0.035
PaCO ₂ , mmHg	58.0 (47.2-68.4)	42.0 (35.0-46.2)	59.4 (55.2-64.2)	78.7 (73.9-84.1)	<0.001
PaO ₂ , mmHg	145.2 (99.3-194.8)	186.1 (139.1-225.8)	145.2 (100.1-180.2)	112.7 (78.2-140.8)	<0.001
pH	7.05 (6.91-7.22)	7.28 (7.21-7.39)	7.02 (6.95-7.10)	6.82 (6.80-6.90)	<0.001
Lactate, mmol/L	8.3 (5.5-11.2)	5.8 (3.5-8.2)	8.5 (6.2-10.8)	11.9 (9.1-14.2)	<0.001
Base excess, mmol/L	-12.3 (-17.5 to -6.9)	-5.9 (-9.8 to -3.2)	-13.2 (-16.5 to -10.0)	-19.8 (-22.3 to -17.1)	<0.001
Cardiac etiology	395 (64.0)	149 (78.0)	185 (64.7)	61 (43.6)	<0.001
Non-cardiac etiology	222 (36.0)	42 (22.0)	101 (35.3)	79 (56.4)	

Data are median (IQR) or n (%). Comparisons: Kruskal-Wallis (continuous) or χ^2 (categorical). Base-excess IQR shown as lower to upper bound. CPR, cardiopulmonary resuscitation; PaCO₂/PaO₂, arterial partial pressure of carbon dioxide/oxygen; ROSC, return of spontaneous circulation.

Table 2: Baseline characteristics by admission PaCO₂ group

Variable	Overall (N = 617)	≤50 mmHg (n = 191)	>50-70 mmHg (n = 286)	>70 mmHg (n = 140)	p
Age, years	67 (57-76)	66 (56-75)	66 (55-75)	72 (60-81)	0.002
Male sex	367 (59.5)	130 (68.1)	167 (58.4)	70 (50.0)	0.004
Witnessed arrest	253 (41.0)	97 (50.8)	120 (42.0)	36 (25.7)	<0.001
Bystander CPR	97 (15.7)	45 (23.6)	40 (14.0)	12 (8.6)	<0.001
Shockable initial rhythm	143 (23.2)	82 (42.9)	45 (15.7)	16 (11.4)	<0.001
Prehospital ROSC	78 (12.6)	45 (23.6)	28 (9.8)	5 (3.6)	<0.001
Call-to-arrival time, min	22.3 (17.8-28.7)	21.6 (17.5-27.2)	21.9 (17.5-28.5)	24.1 (18.8-30.2)	0.035
PaCO ₂ , mmHg	58.0 (47.2-68.4)	42.0 (35.0-46.2)	59.4 (55.2-64.2)	78.7 (73.9-84.1)	<0.001
PaO ₂ , mmHg	145.2 (99.3-194.8)	186.1 (139.1-225.8)	145.2 (100.1-180.2)	112.7 (78.2-140.8)	<0.001
pH	7.05 (6.91-7.22)	7.28 (7.21-7.39)	7.02 (6.95-7.10)	6.82 (6.80-6.90)	<0.001
Lactate, mmol/L	8.3 (5.5-11.2)	5.8 (3.5-8.2)	8.5 (6.2-10.8)	11.9 (9.1-14.2)	<0.001
Base excess, mmol/L	-12.3 (-17.5 to -6.9)	-5.9 (-9.8 to -3.2)	-13.2 (-16.5 to -10.0)	-19.8 (-22.3 to -17.1)	<0.001
Cardiac etiology	395 (64.0)	149 (78.0)	185 (64.7)	61 (43.6)	<0.001
Non-cardiac etiology	222 (36.0)	42 (22.0)	101 (35.3)	79 (56.4)	

Data are median (IQR) or n (%). Comparisons: Kruskal-Wallis (continuous) or χ^2 (categorical). Base-excess IQR shown as lower to upper bound. CPR, cardiopulmonary resuscitation; PaCO₂/PaO₂, arterial partial pressure of carbon dioxide/oxygen; ROSC, return of spontaneous circulation.




Fig. 2. Directed acyclic graph (DAG) of assumed relationships

Measured confounders (age, sex, witnessed status, bystander CPR, rhythm, ROSC, etiology) influence both admission PaCO₂ and outcome. Global ischemia/hypoperfusion (largely unmeasured; e.g. no-flow and low-flow time) and early ventilatory management are common causes of PaCO₂ and of the acid-base markers. Lactate, base excess and pH lie downstream of PaCO₂ and of the shared common cause; conditioning on them (Table 3, model b) adjusts for mediators and for a shared common cause, and is therefore an over-adjustment rather than an estimate of an independent effect.




Fig. 3. One-month outcomes by admission PaCO₂ group

One-month outcomes by admission PaCO₂ group. (A) One-month mortality; (B) unfavorable neurological status (CPC 3-4) among one-month survivors. Mortality $p < 0.001$; survivor neurological outcome $p = 0.026$.

81.1% (232/286), and 90.7% (127/140) ($p < 0.001$; Table 2, Figure 3A). Each 10-mmHg increase in PaCO_2 was associated with higher mortality in unadjusted analysis (OR 1.83, 95% CI 1.59-2.11; $p < 0.001$) and after adjustment for clinical confounders (aOR 1.45, 95% CI 1.24-1.70; $p < 0.001$; Table 3). In the categorical model, the adjusted odds of death were 2.75-fold higher for >50-70 mmHg (95% CI 1.73-4.38) and 4.45-fold higher for >70 mmHg (95% CI 2.18-9.09) relative to ≤ 50 mmHg

(Table 3). In the fully adjusted model, an initial shockable rhythm and prehospital ROSC were, as expected, associated with lower mortality. The adjusted association appeared linear across the observed PaCO_2 range, with no strong evidence of departure from linearity ($p = 0.055$; Figure 4). However, given the strong confounding by arrest severity, this linear gradient should be interpreted as an illness-severity marker rather than a proven causal dose-response.




Fig. 4. Adjusted dose-response (restricted cubic spline)

Adjusted dose-response between admission PaCO_2 and one-month mortality (restricted cubic spline; shaded band, 95% CI). No significant departure from linearity ($p = 0.055$), supporting the per-10-mmHg summary estimate.

Neurological outcomes

Favorable neurological outcome (CPC 1-2) was recorded in 146 patients (23.7%). Because CPC 5 denotes death, the crude proportion with CPC 3-5 rose with PaCO_2 in parallel with mortality (52.4%, 84.3%, 92.9%; Table 2). In the dichotomous analysis, each 10-mmHg increase in PaCO_2 was associated with higher odds of an unfavorable outcome (aOR 1.59, 95% CI 1.34-1.88; $p < 0.001$), and in proportional-odds regression with a shift towards worse CPC (adjusted common OR 1.53, 95% CI 1.31-1.79; $p < 0.001$; Figure 7). The Brant test for the proportional odds assumption yielded $p = 0.78$, confirming that the assumption was met. Among one-month survivors, the risk of unfavorable neurological status (CPC 3-4) also increased with PaCO_2 (5.2%, 16.7%, 23.1%; $p = 0.026$; aOR 1.91 per 10 mmHg, 95%

CI 1.25-2.91; $p = 0.003$; Figure 3B, Supplementary Table S3). This survivor-restricted estimate rests on few events (17 among 163 survivors) and should be interpreted with corresponding caution.

Sensitivity analyses using alternative cut-points

The graded association between PaCO_2 and mortality was preserved across categorization schemes (Figure 5, Supplementary Table S1). Using standard clinical categories (reference ≤ 45 mmHg), the aOR was 1.76 (95% CI 1.04-2.98) for 46-60 mmHg and 3.45 (95% CI 1.94-6.12) for >60 mmHg; using tertiles, the aOR was 3.31 (95% CI 2.00-5.48) for the middle and 3.87 (95% CI 2.17-6.92) for the highest tertile. The continuous per-10-mmHg estimate (aOR 1.45) provides the most efficient summary and avoids information loss.

Effect of adjustment for metabolic acidosis

PaCO₂ was strongly correlated with concurrent acid-base variables (pH, $r = -0.88$; base excess, $r = -0.73$; lactate, $r = 0.52$), and VIFs for pH and base excess exceeded 20. When lactate, base excess, and PaO₂ were added to the clinical model, the association of PaCO₂ with mortality was attenuated to the null (aOR 0.80 per 10 mmHg, 95% CI 0.64-1.01; $p = 0.063$; Figure 5, Supplementary Table S2). Because these markers are largely downstream expressions of the same global hypoperfusion and are strongly collinear with PaCO₂, this model is best interpreted as a conservative sensitivity analysis that likely over-adjusts for shared physiological mediators. We explicitly refrain from interpreting this attenuation as evidence that PaCO₂ lacks an "independent" effect; rather, it confirms the difficulty of disentangling PaCO₂ from global metabolic acidosis in observational data.

Etiology subgroup analysis

The per-10-mmHg association was directionally consistent in both etiology strata but reached significance only in cardiac arrests ($n = 395$; aOR 1.51, 95% CI 1.25-1.84; $p < 0.001$) and not in non-cardiac arrests ($n = 222$; aOR 1.32, 95% CI 0.97-1.80; $p = 0.074$). The interaction

test was not significant ($p = 0.371$), so a differential effect by etiology cannot be claimed (Supplementary Table S4). The dataset contained only cardiac and non-cardiac categories.

Incremental prognostic value

Admission PaCO₂ alone discriminated one-month mortality with an AUC of 0.740 (95% CI 0.695-0.782). A clinical model incorporating age, sex, prehospital variables, rhythm, ROSC, and etiology achieved an AUC of 0.794 (95% CI 0.750-0.834); adding PaCO₂ increased the AUC to 0.816 (95% CI 0.775-0.854), a minimal incremental improvement (Δ AUC 0.022, 95% CI 0.002-0.043; Figure 6, Supplementary Table S5). Internal validation gave an optimism-corrected AUC of 0.802. Calibration of the clinical-plus-PaCO₂ model was assessed via bootstrap validation: calibration slope = 0.98 (95% CI 0.89-1.07), and calibration-in-the-large = -0.04 (95% CI -0.21 to 0.13), indicating adequate agreement between predicted and observed risks (Figure 6B). Given the trivial magnitude of the AUC increase and the absence of decision curve analysis or net reclassification improvement, we consider the clinical utility of adding PaCO₂ to be unproven by this study.

Table 3: Association of admission PaCO₂ with one-month mortality (multivariable models)

Model / specification	OR (95% CI)	p
Continuous, per 10-mmHg increase		
Unadjusted	1.83 (1.59-2.11)	<0.001
Clinically adjusted a	1.45 (1.24-1.70)	<0.001
Clinical + acid-base / gas-exchange markers b	0.80 (0.64-1.01)	0.063
Categorical (reference ≤50 mmHg), clinically adjusted a		
>50-70 mmHg	2.75 (1.73-4.38)	<0.001
>70 mmHg	4.45 (2.18-9.09)	<0.001

^a Adjusted for age, sex, witnessed arrest, bystander CPR, call-to-arrival time, initial shockable rhythm, prehospital ROSC, and etiology. ^b Additional adjustment for lactate, base excess, and PaO₂. Because these markers are strongly collinear with PaCO₂ and largely downstream of the same global hypoperfusion, this model is presented as a conservative sensitivity analysis exploring shared pathophysiology, not as a primary estimate of an "independent" effect. OR, odds ratio; CI, confidence interval.

DISCUSSIONS

This study suggests that elevated admission PaCO₂ is associated with higher one-month mortality and worse neurological outcomes in OHCA patients, with a graded association that parallels illness severity. The association was robust to the choice of cut-points, held for the dichotomous and ordinal neurological endpoints, and persisted among survivors, although the survivor-restricted analysis was exploratory and based on few

events. Adding PaCO₂ to an established clinical model produced a small, statistically significant gain in discrimination of uncertain clinical importance. These findings extend prior work relating peri-arrest PaCO₂ to outcome [8, 9, 11, 12]. Whereas several earlier studies dichotomized exposure or focused on hypocapnia, we quantified a continuous risk gradient and found that each 10-mmHg rise in PaCO₂ raised the adjusted odds of death by roughly 45%. Our results are consistent with Inoue et al., who reported that a higher PCO₂ on arrival predicted one-month mortality and unfavorable neurological outcome in OHCA [13], and

Continuous, per 10 mmHg increase

Unadjusted
Clinically adjusted
+ Metabolic markers

Categories (ref ≤ 50 mmHg)

> 50–70 mmHg
> 70 mmHg

Clinical cutoffs (ref ≤ 45 mmHg)

46–60 mmHg
> 60 mmHg

Tertiles (ref T1 ≤ 51.5 mmHg)

T2 (51.6–64.5)
T3 (64.6–101.6)




Fig. 5. Adjusted odds ratios for one-month mortality across model specifications

Adjusted odds ratios for one-month mortality across model specifications and categorisation schemes (forest plot; log scale). Models are adjusted for age, sex, witnessed arrest, bystander CPR, call-to-arrival time, initial shockable rhythm, pre-hospital ROSC and aetiology; the metabolic-markers model additionally adjusts for lactate, base excess and PaO₂.




Fig. 6. Prognostic performance for one-month mortality

Prognostic performance for one-month mortality. (A) Receiver-operating-characteristic curves for PaCO₂ alone, the clinical model and the clinical model plus PaCO₂; (B) calibration plot for the clinical-plus-PaCO₂ model. AUC: PaCO₂ 0.740, clinical 0.794, clinical + PaCO₂ 0.816 (optimism-corrected 0.802). Calibration of the clinical-plus-PaCO₂ model: calibration slope 0.98 (95% CI 0.89–1.07), calibration-in-the-large -0.04 (95% CI -0.21 to 0.13).




Fig. 7. Distribution of one-month Cerebral Performance Category by PaCO₂

Distribution of one-month Cerebral Performance Category by admission PaCO₂ group. Ordinal common OR 1.53 (95% CI 1.31-1.79) per 10 mmHg, indicating a gradient towards worse CPC as PaCO₂ rises; CPC 5 = death.

with registry and ICU cohorts describing outcome associations for admission carbon-dioxide tension [11, 12]. The most important nuance is mechanistic and is subject to two competing interpretations, which our observational data cannot adjudicate. First, the "mediator overadjustment" interpretation: The independent PaCO₂ association was substantially attenuated once metabolic-acidosis markers entered the model, and PaCO₂ was very strongly correlated with pH and base excess. If lactate and base excess lie on the causal pathway between hypercapnia and death (e.g., hypercapnia exacerbating acidosis, which worsens myocardial function), then adjusting for them would inappropriately block the very effect we are attempting to estimate. This would make the attenuation an artifact of overadjustment. Second, the "surrogate marker" interpretation: Lactate and base excess are largely downstream consequences of the same global hypoperfusion rather than independent confounders. Under this view, PaCO₂ is simply a non-causal epiphenomenon of global metabolic collapse; once the severity of that collapse is captured by lactate and base excess, PaCO₂ adds no further information. This would mean PaCO₂ is a useful early warning signal but not a distinct driver of injury. Given the strong collinearity and the post-resuscitation timing of the measurement, we cannot distinguish between these two interpretations. The

most defensible conclusion is that admission PaCO₂ is chiefly a marker of the severity of global ischemia and impaired CO₂ clearance. Our data do not support its use as a proven therapeutic target for ventilation titration, nor do they rule out a modest causal contribution. Clinically, admission PaCO₂ is practical because it is immediate, inexpensive, and universally available from the first blood gas. However, its modest incremental discrimination and the unresolved confounding by post-resuscitation care indicate it should be used cautiously—as a complementary prognostic signal rather than a replacement for multivariable assessment. Importantly, this retrospective dataset could not distinguish spontaneous (pathological) hypercapnia from controlled permissive hypercapnia, and ventilator parameters were unavailable, a clinically meaningful distinction that warrants prospective study[6, 7]

■ LIMITATIONS

This study has several limitations. It is retrospective and single-center, which limits generalizability. Detailed comorbidity, shock on admission, and targeted temperature management were unavailable; outcome ascertainment was restricted to one month; only two etiology categories were available; and the survivor-restricted analysis rests on few events. PaCO₂ was

strongly collinear with acid-base variables, such that its contribution cannot be separated from global acidosis. Decision-curve analysis was not performed, which together with the trivial Δ AUC (0.022) precludes any claim of clinical utility.

The principal limitation, however, is intrinsic to the exposure. Admission PaCO_2 is not a fixed baseline characteristic but a product of the resuscitation itself, determined by: (1) the duration of arrest and of CPR (no-flow and low-flow intervals); (2) the quality of chest compressions and the resulting pulmonary CO_2 delivery; (3) the mode and timing of airway management; (4) the ventilation delivered during and after CPR; (5) the initial ventilator settings; and (6) the interval between ROSC and arterial sampling. None of these variables was recorded, and none can be reconstructed retrospectively. A comparison of high and low admission PaCO_2 is therefore not a comparison of otherwise similar patients but, in unquantifiable degree, a comparison between resuscitations that differed in duration, quality, and ventilatory management. The observed association may thus reflect resuscitation quality and arrest severity rather than any prognostic property of PaCO_2 itself. We accordingly make no claim of independent prognostic value: establishing this would require prospective data capturing resuscitation timings, CPR quality, ventilation, and the ROSC-to-sampling interval.

■ 5. CONCLUSION

In this decade-long cohort, higher admission PaCO_2 was associated with increased one-month mortality and worse neurological outcome after OHCA in analyses adjusted for measured confounders, but added minimal discrimination beyond established clinical factors. Because admission PaCO_2 is a treatment-dependent exposure determined by CPR duration and quality, airway and ventilation management, ventilator settings, and the ROSC-to-sampling interval, none of which were available in this retrospective dataset, independent prognostic value cannot be established from these data, and the association is most plausibly a signal of arrest severity and of the resuscitation delivered. Attenuation of the association after adjustment for metabolic acidosis is consistent with shared pathophysiology, although mediator overadjustment cannot be excluded.

Admission PaCO_2 is immediate, inexpensive, and universally available from the first blood gas, and a

markedly elevated value should be read as corroborating what the prehospital history already indicates: a prolonged, poorly perfused arrest. Prospective, multicenter studies capturing resuscitation timings, CPR quality, and standardized ventilation are required before any prognostic role for admission PaCO_2 can be claimed, and before it could be considered as a target for ventilatory management.

■ AUTHOR CONTRIBUTIONS

M.L.: Conceptualization, Formal Analysis, Writing - Original Draft, Writing - Review & Editing.

Q.H.: Methodology, Investigation, Data Curation, Writing - Review & Editing.

L.D.: Investigation, Resources, Writing - Review & Editing

■ CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest related to this study. There are no financial or personal relationships with other people or organizations that could inappropriately influence (bias) our work.

■ ETHICS APPROVAL AND CONSENT TO PARTICIPATE

This retrospective cohort study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board (IRB) / Ethics Committee of Peking University Hospital of Marine Oil. The need for informed consent was waived by the ethics committee due to the retrospective nature of the study, which involved no more than minimal risk to the subjects and for which the research could not practically be carried out without the waiver. All patient data were anonymized and de-identified prior to analysis.

■ FUNDING

This research received no external funding.

■ REFERENCES

1. Feng X-F, Hai J-J, Ma Y, Wang Z-Q, Tse H-F. Sudden cardiac death in mainland China: a systematic analysis. *Circulation: Arrhythmia and Electrophysiology*. 2018;11(11):e006684.
2. Rea T, Kudenchuk PJ, Sayre MR, Doll A, Eisenberg M. Out of

- hospital cardiac arrest: Past, present, and future. *Resuscitation*. 2021;165:101-9.
3. Guoxiang L, Zhangqing Z, Shiwei W, Tianyuan J, Chengzhun L, Zida W, et al. Research progress in post cardiac arrest syndrome associated with acute gastrointestinal injury. *J Clin Emerg*. 2021;22(9):634-40.
 4. Soar J, Berg KM, Andersen LW, Böttiger BW, Cacciola S, Callaway CW, et al. Adult advanced life support: 2020 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. *Resuscitation*. 2020;156:A80-A119.
 5. Soar J, Böttiger BW, Carli P, Couper K, Deakin CD, Djärv T, et al. European resuscitation council guidelines 2021: adult advanced life support. *Resuscitation*. 2021;161:115-51.
 6. Aufderheide TP, Lurie KG. Death by hyperventilation: a common and life-threatening problem during cardiopulmonary resuscitation. *Critical care medicine*. 2004;32(9):S345-S51.
 7. Bartos JA, Grunau B, Carlson C, Duval S, Ripeckyj A, Kalra R, et al. Improved survival with extracorporeal cardiopulmonary resuscitation despite progressive metabolic derangement associated with prolonged resuscitation. *Circulation*. 2020;141(11):877-86.
 8. Roberts BW, Kilgannon JH, Chansky ME, Mittal N, Wooden J, Trzeciak S. Association between postresuscitation partial pressure of arterial carbon dioxide and neurological outcome in patients with post-cardiac arrest syndrome. *Circulation*. 2013;127(21):2107-13.
 9. Lee BK, Jeung KW, Lee HY, Lee SJ, Jung YH, Lee WK, et al. Association between mean arterial blood gas tension and outcome in cardiac arrest patients treated with therapeutic hypothermia. *The American journal of emergency medicine*. 2014;32(1):55-60.
 10. Eastwood GM, Schneider A, Bellomo R. Arterial carbon dioxide tension and outcome in patients admitted to the intensive care unit after cardiac arrest (reply). *Resuscitation*. 2013;84(9):e105.
 11. Vaahersalo J, Bendel S, Reinikainen M, Kurola J, Tiainen M, Raj R, et al. Arterial blood gas tensions after resuscitation from out-of-hospital cardiac arrest: associations with long-term neurologic outcome. *Critical care medicine*. 2014;42(6):1463-70.
 12. Okada N, Matsuyama T, Okada Y, Okada A, Kandori K, Nakajima S, et al. Post-Resuscitation Partial Pressure of Arterial Carbon Dioxide and Outcome in Patients with Out-of-Hospital Cardiac Arrest: A Multicenter Retrospective Cohort Study. *J Clin Med*. 2022;11(6).
 13. Inoue F, Inoue A, Nishimura T, Takahashi R, Nakatani Y, Suga M, et al. PCO₂ on arrival as a predictive biomarker in patients with out-of-hospital cardiac arrest. *The American Journal of Emergency Medicine*. 2023;69:92-9.

SUPPLEMENTARY MATERIAL

Admission Arterial Partial Pressure of Carbon Dioxide (PaCO₂) and Outcomes After Out-of-Hospital Cardiac Arrest: A Single-Centre Retrospective Cohort Study

Table S1. Sensitivity analyses - association of PaCO₂ with one-month mortality using alternative categorisations

PaCO ₂ specification	Adjusted OR (95% CI)*	p
Data-driven groups (ref ≤ 50 mmHg)		
> 50-70 mmHg (n=286)	2.75 (1.73-4.38)	<0.001
> 70 mmHg (n=140)	4.45 (2.18-9.09)	<0.001
Clinical cutoffs (ref ≤ 45 mmHg, n=136)		
46-60 mmHg (n=205)	1.76 (1.04-2.98)	0.035
> 60 mmHg (n=276)	3.45 (1.94-6.12)	<0.001
Tertiles (ref T1, 18-51.5 mmHg)		
T2 (51.6-64.5 mmHg)	3.31 (2.00-5.48)	<0.001
T3 (64.6-101.6 mmHg)	3.87 (2.17-6.92)	<0.001
Continuous, per 10 mmHg	1.45 (1.24-1.70)	<0.001

*Adjusted for age, sex, witnessed arrest, bystander CPR, call-to-arrival time, shockable rhythm, prehospital ROSC and etiology. Reference categories indicated in parentheses. The graded association is preserved across all cut-point schemes and in the continuous model, indicating results are not an artefact of a particular categorisation.

Table S2. Effect of adjustment for concurrent metabolic acidosis on the PaCO₂-mortality association (per 10 mmHg)

Model	Adjusted OR (95% CI)	p
Clinical model*	1.45 (1.24-1.70)	<0.001
Clinical model + lactate, base excess, PaO ₂ †	0.80 (0.64-1.01)	0.063

*Clinical model: age, sex, witnessed arrest, bystander CPR, call-to-arrival time, shockable rhythm, prehospital ROSC, etiology. †Additional adjustment for lactate, base excess and PaO₂. PaCO₂ was strongly collinear with these acid-base variables (Pearson r with pH -0.88; base excess -0.73; lactate 0.52; variance-inflation factors for pH and base excess > 20). Because lactate and base excess are largely downstream of the same global hypoperfusion, this model likely over-adjusts for mediators and is presented as a conservative test of independence rather than as the primary estimate.

Table S3. Neurological outcome analyses (PaCO₂ per 10 mmHg)

Analysis	Unadjusted OR (95% CI)	p	Adjusted OR (95% CI)*	p
Ordinal CPC (1-5), common OR	1.93 (1.68-2.23)	<0.001	1.53 (1.31-1.79)	<0.001
Unfavourable neurological outcome (CPC 3-5)	-	-	1.59 (1.34-1.88)	<0.001
Unfavourable CPC among survivors (3-4)	-	-	1.91 (1.25-2.91)	0.003

**Adjusted for age, sex, witnessed arrest, bystander CPR, shockable rhythm, prehospital ROSC, and etiology (call-to-arrival time additionally included for mortality/unfavorable outcome models). Ordinal CPC analyzed by proportional-odds regression. The survivor-only analysis (CPC 3-4 among one-month survivors, n = 163) was analyzed using Firth's penalized logistic regression due to the low number of events (n=17), demonstrating that the association is not solely attributable to competing mortality.*

Table S4. Subgroup analysis by arrest etiology (PaCO₂ per 10 mmHg, one-month mortality)

Etiology subgroup	Adjusted OR (95% CI)*	p
Cardiac (n=395; 260 deaths)	1.51 (1.25-1.84)	<0.001
Non-cardiac (n=222; 194 deaths)	1.32 (0.97-1.80)	0.074

*Adjusted for age, sex, witnessed arrest, bystander CPR, call-to-arrival time, shockable rhythm and prehospital ROSC. Test for PaCO₂ × etiology interaction: p = 0.371. The confidence intervals overlap substantially and the interaction is not significant; a differential effect by etiology cannot be claimed. Only cardiac and non-cardiac categories were available in the dataset.

Table S5. Discrimination for one-month mortality (area under the ROC curve)

Model	AUC (95% CI)
Admission PaCO ₂ alone	0.740 (0.695-0.782)
Clinical model*	0.794 (0.750-0.834)
Clinical model + PaCO ₂	0.816 (0.775-0.854)

*Clinical model: age, sex, witnessed arrest, bystander CPR, call-to-arrival time, shockable rhythm, prehospital ROSC, etiology. Adding admission PaCO₂ to the clinical model improved discrimination by ΔAUC 0.022 (0.002-0.043), a minimal improvement of uncertain clinical utility.

Table S6. Comparison of included patients (n=617) versus patients excluded due to missing admission ABG or one-month outcome data

Characteristic	Included (n=617)	Excluded (n=84)	P value
Age, years	67(57-76)	66(55-74)	0.38
Male sex	367(59.5%)	44(52.4%)	0.21
Witnessed arrest	253(41.0%)	32(38.1%)	0.62
Shockable rhythm	143(23.2%)	17(20.2%)	0.55
Prehospital ROSC	78(12.6%)	8(9.5%)	0.42
Cardiac etiology	395(64.0%)	51(60.7%)	0.55

Data are median (IQR) or n (%). Comparisons: Mann-Whitney U (continuous) or χ^2 (categorical). No statistically significant differences were observed between included and excluded patients, suggesting that complete case analysis did not introduce substantial selection bias on measured characteristics.

Supplementary Note. Variable availability

All analyses were performed on the complete de-identified dataset (N = 617). The following variables were available and analyzed: age, sex, witnessed arrest, bystander CPR, shockable initial rhythm, prehospital ROSC, call-to-arrival time, arrest etiology (cardiac vs non-cardiac), admission PaCO₂, PaO₂, pH, lactate, base excess, one-month mortality, and one-month CPC. Variables often recommended for OHCA prognostication but not present in this dataset—including detailed comorbidity, airway-management type, shock on admission, no-flow/low-flow intervals, targeted tempera-

ture management, and ventilator settings, could not be included and are acknowledged as limitations. As noted in the main manuscript, the absence of no-flow/low-flow intervals, ventilator settings, and ROSC-to-ABG time is a major limitation that precludes disentangling the prognostic signal of PaCO₂ from resuscitative treatment effects.